clinical trial · NCT06701526
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
H. Lundbeck A/S·phase4·active not recruiting·n = 150
MigraineEptinezumab
brief summary
The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies targeting calcitonin gene-related peptide (CGRP).
started
Dec 18, 2024
primary completion
Jun 5, 2026
completion
Jun 5, 2026
last updated
Mar 9, 2026
official title
Interventional, Open-label Trial, Investigating the Effectiveness of Eptinezumab in Participants With Migraine and Previous Inadequate Response to CGRP-targeting Therapies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol